SanBio Co., Ltd. engages in the development, production and sale of regenerative cells medicines. The company is headquartered in Chuo-Ku, Tokyo-To and currently employs 29 full-time employees. The company went IPO on 2015-04-08. The firm has the research and development base in the United States and conducts research, development, manufacture and sale of regenerative cell medicines in Japan. The firm aims to sell therapeutic agents for diseases with high unmet medical needs, mainly in diseases of the central nervous system. The company is involved in the manufacture, development, non-clinical studies, clinical trials of technologies introduced from research institutes such as universities. The firm has five regenerative cell drugs, including the main product candidate SB623 (nerve regenerative cells), SB618 (function-enhancing type & Mesenchymal stem cells), SB308 (muscle stem cells), MSC1 (mesenchymal stem cells), and MSC2 (mesenchymal stem cells).
Follow-Up Questions
Qui est le CEO de SanBio Co Ltd ?
Mr. Keita Mori est le President de SanBio Co Ltd, il a rejoint l'entreprise depuis 2013.
Quelle est la performance du prix de l'action SNBIF ?
Le prix actuel de SNBIF est de $0, il a decreased de 0% lors de la dernière journée de trading.
Quels sont les thèmes d'affaires principaux ou les industries de SanBio Co Ltd ?
SanBio Co Ltd appartient à l'industrie Biotechnology et le secteur est Health Care
Quel est la capitalisation boursière de SanBio Co Ltd ?
La capitalisation boursière actuelle de SanBio Co Ltd est de $0
Est-ce que SanBio Co Ltd est un achat, une vente ou un maintien ?
Selon les analystes de Wall Street, 6 analystes ont établi des notations d'analystes pour SanBio Co Ltd, y compris 0 achat fort, 0 achat, 4 maintien, 3 vente et 0 vente forte
